<DOC>
	<DOCNO>NCT02427165</DOCNO>
	<brief_summary>The number people asthma allergy still increase large number patient still asthma well control . There therefore need new asthma treatment work well less side effect . The study compare new experimental drug RPL554 market asthma drug ( salbutamol ) placebo .</brief_summary>
	<brief_title>Comparison RPL554 With Placebo Salbutamol Asthmatic Patients</brief_title>
	<detailed_description>A seven way crossover study investigate pharmacodynamics , pharmacokinetics , safety tolerability inhale RPL554 compare salbutamol placebo patient mild moderate chronic asthma . Salbutamol market beta-2 agonist typically use treat bronchospasm ( due cause , allergen asthma exercise-induced ) , well chronic obstructive pulmonary disease associate dose-related systemic side effect . RPL554 dual PDE3 PDE4 inhibitor bronchodilatory anti-inflammatory action also potential stimulate increase mucociliary clearance via proven ability activate CFTR . Four different dos RPL554 compare placebo two dos salbutamol benchmark bronchodilation systemic side effect .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Provided write informed consent Males agree donate sperm either abstinent use adequate contraception . Females postmenopausal surgically sterile Nonsmoker exsmoker &gt; 6 month Diagnosed asthma least 6 month Prebronchodilator FEV1 ≥60 % ≤90 % predict normal value ≥1.5 L screen Increase FEV1 15 % within 30 minute 2.5mg dose nebulised salbutamol Systolic blood pressure 90 145 mmHg , diastolic blood pressure 50 90 mmHg heart rate 45 80 beat per minute ( bpm ) rest 5 minute supine position ( average two measurement ) Capable withdraw LABAs , LAMAs SAMAs screen study SABAs screen 8 hour dose Asthma exacerbation last 3 month Any prior life threaten episode asthma ( intensive care admission ) Any clinically significant disease disorder clinically relevant screen result QTcF interval &gt; 450 m QT interval &gt; 500 m abnormality ECG History ischemic heart disease heart failure . History recurrent current clinically significant arrhythmia ECG abnormality judge investigator Treatment systemic glucocorticosteroids within 30 day screen A suspected/manifested infection accord WHO risk classification 2 , 3 4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>